Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Eurofins Ntd Llc |
RCV000676419 | SCV000860437 | uncertain significance | not provided | 2018-03-15 | criteria provided, single submitter | clinical testing | |
Gene |
RCV000676419 | SCV001871104 | uncertain significance | not provided | 2024-03-04 | criteria provided, single submitter | clinical testing | In silico analysis supports a deleterious effect on protein structure/function; Has not been previously published as pathogenic or benign to our knowledge |
Labcorp Genetics |
RCV000676419 | SCV002217489 | uncertain significance | not provided | 2022-10-13 | criteria provided, single submitter | clinical testing | This sequence change replaces alanine, which is neutral and non-polar, with glutamic acid, which is acidic and polar, at codon 88 of the EARS2 protein (p.Ala88Glu). This variant is present in population databases (no rsID available, gnomAD 11%), and has an allele count higher than expected for a pathogenic variant. This variant has not been reported in the literature in individuals affected with EARS2-related conditions. ClinVar contains an entry for this variant (Variation ID: 559205). Algorithms developed to predict the effect of missense changes on protein structure and function are either unavailable or do not agree on the potential impact of this missense change (SIFT: "Not Available"; PolyPhen-2: "Benign"; Align-GVGD: "Not Available"). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Ce |
RCV000676419 | SCV004141316 | uncertain significance | not provided | 2022-08-01 | criteria provided, single submitter | clinical testing | |
Mayo Clinic Laboratories, |
RCV000676419 | SCV000802197 | benign | not provided | 2016-03-11 | no assertion criteria provided | clinical testing |